0001140361-21-006728.txt : 20210301
0001140361-21-006728.hdr.sgml : 20210301
20210301190341
ACCESSION NUMBER: 0001140361-21-006728
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coiante Scott M
CENTRAL INDEX KEY: 0001608536
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 21700422
MAIL ADDRESS:
STREET 1: 101 POOR FARM ROAD 3RD FLOOR
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
form4.xml
FORM 4
X0306
4
2021-02-25
0001781983
Aprea Therapeutics, Inc.
APRE
0001608536
Coiante Scott M
535 BOYLSTON STREET
BOSTON
MA
02116
true
SVP, Chief Financial Officer
Common Stock
2021-02-25
4
A
0
33000
0
A
35500
D
Common Stock
2021-02-25
4
A
0
63500
0
A
99000
D
Stock Option (right to Buy)
6
2021-02-25
4
A
0
143000
0
A
2031-02-25
Common Stock
143000
143000
D
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
/s/ Scott M. Coiante
2021-03-01